Comparing two chemo treatments for triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a combination of two chemotherapy drugs (cisplatin and gemcitabine) is better than the usual single drug (capecitabine) after surgery for people with triple negative breast cancer who still have cancer cells left after chemotherapy before surgery. The goal is to see if the extra treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 20 years old.
- Your breast cancer must be triple negative (ER and PR less than 1%, HER2 score 0 or 1).
- Your cancer must be an early-stage type (stage I to IIIB) and operable (can be removed with surgery).
- You must not have had inflammatory breast cancer or cancer that has spread to distant organs.
- After your chemotherapy before surgery, you must still have cancer cells left (no complete response).
- You must be generally healthy (good performance status) and have normal heart, kidney, liver, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether adding more treatment after surgery can help people with triple-negative breast cancer who still have cancer cells left after initial chemotherapy and immunotherapy. It aims to reduce the chance of cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.